Evidence map›Paper›PMID 40612249›Full record

ArticleUrology case reports2025

Fibroblast-directed PET imaging reveals a case of retroperitoneal fibrosis after immunotherapy for metastatic urothelial cancer of the upper tract.

L Gallardo Zamora, F C von Rundstedt, C Wach, W P Fendler, I Maric, K Herrmann, J T Siveke, P F-Y Cheung, V Grünwald

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

L Gallardo ZamoraUniversitätsklinikum Wuppertal, Wuppertal, Germany.
F C von RundstedtUniversitätsklinikum Wuppertal, Wuppertal, Germany.
C WachUniversitätsklinikum Wuppertal, Wuppertal, Germany.
W P FendlerUniversitätsklinikum Essen, Essen, Germany.
I MaricUniversitätsklinikum Essen, Essen, Germany.
K HerrmannUniversitätsklinikum Essen, Essen, Germany.
J T SivekeUniversitätsklinikum Essen, Essen, Germany.
P F-Y CheungUniversitätsklinikum Essen, Essen, Germany.
V GrünwaldUniversitätsklinikum Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urothelial carcinomas of the upper urinary tract (UTUC) are relatively rare and challenging to treat. We present a case report of a 55-year-old male patient with high-grade renal UTUC who received adjuvant pembrolizumab immunotherapy. The patient developed retroperitoneal fibrosis as an immune-related adverse event (irAE) following treatment. To better understand the extent of fibrosis, we utilized

Indexed as

68Ga FAPI-46 PET/CTImmune-related adverse eventPembrolizumabRetroperitoneal fibrosisUpper urinary tractUrothelial carcinoma

Identifiers

PMID40612249
PMCPMC12221662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.